ArticleHuman vaccines & immunotherapeutics2016
Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States.
Article in Human vaccines & immunotherapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association between Human Papilloma Virus (HPV) vaccination and risk of Multiple Sclerosis: A systematic review.Human vaccines & immunotherapeutics · 2018Pooled it
- Human Papillomavirus vaccination clinical decision support for young adults in an upper midwestern healthcare system: a clinic cluster-randomized control trial.Human vaccines & immunotherapeutics · 2022Trial
- Pharmacovigilance signal detection of central nervous system demyelinating diseases following human papillomavirus vaccination: data mining and signal analysis based on the VAERS database.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Iranian women's perceptions of human papillomavirus and barriers to vaccination: a qualitative study based on the health belief model.BMC public health · 2025Article
- Prevalence of HPV in anal cancer: exploring the role of infection and inflammation.Infectious agents and cancer · 2024Review
- Advances and challenges in cancer immunoprevention and immune interception.Journal for immunotherapy of cancer · 2024Review
- Evaluation of Theoretical Frameworks to Detect Correlates of HPV Vaccination in the Midwest, US, Using Structural Equation Modeling.Vaccines · 2023Article
- Can prophylactic HPV vaccination reduce the recurrence of cervical lesions after surgery? Review and prospect.Infectious agents and cancer · 2023Review
- Myasthenia gravis after the third dose of human papillomavirus 9-valent vaccine: A case report.Human vaccines & immunotherapeutics · 2023Article
- Updates in Cervical Cancer Screening Guidelines, The Bethesda System for Reporting Cervical Cytology, and Clinical Management Recommendations.Journal of clinical and translational pathology · 2023Article
- Human Papillomavirus Vaccination.The New England journal of medicine · 2023Review
- Barriers to the HPV vaccination program in the Eastern Mediterranean region: a narrative reviewJournal of the Turkish German Gynecological Association · 2023Article
- HPV vaccination coverage and factors among American Indians in Cherokee Nation.Cancer causes & control : CCC · 2023Article
- Updates on HPV Vaccination.Diagnostics (Basel, Switzerland) · 2023Review
- Two centuries of vaccination: historical and conceptual approach and future perspectives.Frontiers in public health · 2023Review
- Designing and psychometric assessment of the scale of factors influencing HPV vaccine uptake behaviors in young adults.Infectious agents and cancer · 2022Article
- Article
- Curbing an outbreak of circulating vaccine derived poliovirus type 2 in Dollo Zone, Somali Region, Ethiopia: response to outbreak.The Pan African medical journal · 2022Article
- Attitudes Toward HPV Vaccination in Sweden: A Survey Study.Frontiers in public health · 2022Article
- Significant Declines in Juvenile-onset Recurrent Respiratory Papillomatosis Following Human Papillomavirus (HPV) Vaccine Introduction in the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Quadrivalent human papillomavirus (4vHPV) vaccine was licensed for use in the United States in 2006 and through 2015 was the predominate HPV vaccine used. With the exception of syncope, a known preventable adverse event after any injected vaccination, both pre-licensure and post-licensure 4vHPV safety data have been reassuring with no confirmed safety signals identified. Nine-valent HPV vaccine (9vHPV) was licensed in 2014. This review includes post-licensure 4vHPV safety findings published to date that have informed the US vaccination program; these data will inform US safety monitoring and evaluation for 9vHPV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.